We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease.
- Authors
Salihovic, Samira; Nyström, Niklas; Mathisen, Charlotte Bache-Wiig; Kruse, Robert; Olbjørn, Christine; Andersen, Svend; Noble, Alexandra J.; Dorn-Rasmussen, Maria; Bazov, Igor; Perminow, Gøri; Opheim, Randi; Detlie, Trond Espen; Huppertz-Hauss, Gert; Hedin, Charlotte R. H.; Carlson, Marie; Öhman, Lena; Magnusson, Maria K.; Keita, Åsa V.; Söderholm, Johan D.; D'Amato, Mauro
- Abstract
Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making. Diagnostic blood-based biomarkers of pediatric IBD are limited. Here, the authors demonstrate a diagnostic lipidomic signature, comprising only of two molecular lipids. Translation of this signature into a scalable test has the potential to support clinical decision making.
- Subjects
INFLAMMATORY bowel diseases; CLINICAL decision support systems; BLOOD testing; C-reactive protein; CHILD patients
- Publication
Nature Communications, 2024, Vol 15, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-024-48763-7